CCR 20th Anniversary Commentary: Vorinostat—Gateway to epigenetic therapy Journal Article
| Authors: | Kelly, W. K.; Marks, P.; Richon, V. M. |
| Article Title: | CCR 20th Anniversary Commentary: Vorinostat—Gateway to epigenetic therapy |
| Abstract: | The study by Kelly and colleagues, published in the September 1, 2003, issue of Clinical Cancer Research, established the safety and biologic activity of the first-in-class histone deacetylase inhibitor, vorinostat, which was administered intravenously. Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors. (C)2015 AACR. |
| Keywords: | histone deacetylase inhibitor; lymphoma; trial; phase-i; t-cell; suberoylanilide hydroxamic acid; saha; cancer |
| Journal Title: | Clinical Cancer Research |
| Volume: | 21 |
| Issue: | 10 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2015-05-15 |
| Start Page: | 2198 |
| End Page: | 2200 |
| Language: | English |
| ACCESSION: | WOS:000357335500002 |
| DOI: | 10.1158/1078-0432.ccr-14-2556 |
| PROVIDER: | wos |
| PUBMED: | 25979925 |
| Notes: | Editorial Material -- Source: Wos |
